Emmaus Life Sciences Reports Q2 2023 Financial Results

Record Net Revenues Contributed to Income from Operations Sixth Straight Quarterly Increase in Net Revenues TORRANCE, Calif., Aug. 14, 2023 /PRNewswire/ — Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell…

Click here to view original post